Floatz logo

SIMVASTATIN

Coronary Artery Disorder

University of WashingtonSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Coronary Artery Disorder cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Ezetimibe
Canadian Collaborative Research Network
Phase 4BBB
Rivaroxaban
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 4BBB
Ranolazine
OBS Pakistan
Phase 4BBB
PITAVASTATIN
Yokohama City University Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →